Home Newsfeeds Needham Reiterates Buy on Cormedix, Maintains $13 Price Target

Needham Reiterates Buy on Cormedix, Maintains $13 Price Target

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:CRMD) with a Buy and maintains $13 price target.

byBenzinga Newsdesk

March 3, 2023

1 minute read

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:CRMD) with a Buy and maintains $13 price target.

LianBio Announces Topline Results From Phase 3 LIBRA Trial Of TP-03 In Chinese Patients With Demodex Blepharitis; The Co-primary Endpoints Of The LIBRA Trial Were Mite Eradication And Complete Collarette Cure At Day 43

By Benzinga Newsdesk

October 30, 4:54 PM

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced topline results from the Phase 3 LIBRA clinical trial

LIAN

Adial Pharmaceuticals Announces 1-For-25 Reverse Stock Split To Regain Compliance With Nasdaq’s Minimum Bid Price Requirement And Reduce The Public Float

By Happy Mohamed

August 4, 8:34 AM

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of

ADIL

Biden’s Plan To Help Taxpayers At The Gas Pump Comes As Strategic Reserves Fall To 1984 Levels

By Robert Kuczmarski

October 21, 4:15 PM

President Joe Biden announced on Oct. 19 the release of 15 million barrels of oil from the strategic petroleum reserve (SPR) due to recent production cuts announced by the OPEC + coalition.

XOM

Ericsson Nomination Committee’s Proposal For Board Of Directors. Jan Carlson Proposed As New Chairman; Chairman, Ronnie Leten, Has Informed That He Will Not Stand For Re-Election To The Board

By Benzinga Newsdesk

January 11, 11:47 AM

Chairman, Ronnie Leten, has informed that he will not stand for re-election to the Board Kurt Jofs and Nora Denzel have informed the Nomination Committee

ERIC

Needham Reiterates Buy on Cormedix, Maintains $13 Price Target

Related Posts

LianBio Announces Topline Results From Phase 3 LIBRA Trial Of TP-03 In Chinese Patients With Demodex Blepharitis; The Co-primary Endpoints Of The LIBRA Trial Were Mite Eradication And Complete Collarette Cure At Day 43

Adial Pharmaceuticals Announces 1-For-25 Reverse Stock Split To Regain Compliance With Nasdaq’s Minimum Bid Price Requirement And Reduce The Public Float

Biden’s Plan To Help Taxpayers At The Gas Pump Comes As Strategic Reserves Fall To 1984 Levels

Ericsson Nomination Committee’s Proposal For Board Of Directors. Jan Carlson Proposed As New Chairman; Chairman, Ronnie Leten, Has Informed That He Will Not Stand For Re-Election To The Board